AR117808A1 - RECOMBINANT VACCINE VIRUS AND METHODS OF USE OF THE SAME - Google Patents

RECOMBINANT VACCINE VIRUS AND METHODS OF USE OF THE SAME

Info

Publication number
AR117808A1
AR117808A1 ARP200100080A ARP200100080A AR117808A1 AR 117808 A1 AR117808 A1 AR 117808A1 AR P200100080 A ARP200100080 A AR P200100080A AR P200100080 A ARP200100080 A AR P200100080A AR 117808 A1 AR117808 A1 AR 117808A1
Authority
AR
Argentina
Prior art keywords
methods
same
vaccine virus
recombinant vaccine
present disclosure
Prior art date
Application number
ARP200100080A
Other languages
Spanish (es)
Original Assignee
Ignite Inmunotherapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignite Inmunotherapy Inc filed Critical Ignite Inmunotherapy Inc
Publication of AR117808A1 publication Critical patent/AR117808A1/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona un virus de vacuna oncolítico recombinante, competente a la replicación; y composiciones que comprenden el virus de vacuna oncolítico recombinante, competente a la replicación. La presente descripción también proporciona el uso del virus de vacuna o composición para inducir la oncólisis en un individuo que tiene un tumor.The present disclosure provides a replication competent, recombinant oncolytic vaccinia virus; and compositions comprising replication competent recombinant oncolytic vaccinia virus. The present disclosure also provides the use of the vaccine virus or composition to induce oncolysis in an individual having a tumor.

ARP200100080A 2019-01-14 2020-01-13 RECOMBINANT VACCINE VIRUS AND METHODS OF USE OF THE SAME AR117808A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962792287P 2019-01-14 2019-01-14

Publications (1)

Publication Number Publication Date
AR117808A1 true AR117808A1 (en) 2021-08-25

Family

ID=77568369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100080A AR117808A1 (en) 2019-01-14 2020-01-13 RECOMBINANT VACCINE VIRUS AND METHODS OF USE OF THE SAME

Country Status (1)

Country Link
AR (1) AR117808A1 (en)

Similar Documents

Publication Publication Date Title
AR108630A1 (en) GENETICALLY MODIFIED VACCINIA VIRUSES
BR112019001737A2 (en) pten-long expression with oncolytic viruses
CL2018000587A1 (en) Oncolytic adenovirus encoding a b7 protein (divisional sol. No. 2731-2017)
CL2017001819A1 (en) New peptides and new combinations of peptides for use in immunotherapy against lung cancer, including amicrocytic lung cancer and other types of cancer
BR112018011122A2 (en) antigens, vectors, compositions, and methods of use for the human immunodeficiency virus thereof
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
MX2018010204A (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy.
UY36538A (en) HUMAN ANTIBODIES AGAINST THE GLICOPROTEIN OF THE ÉBOLA VIRUS
UY35964A (en) HUMAN ANTIBODIES FOR PD? 1
BR112017018160A2 (en) use of inactivated non-replicating modified vaccinia ankara virus (mva) as monoimmunotherapy or in combination with solid tumor immune checkpoint blocking agents
MX2021001883A (en) Recombinant myxoma viruses and uses thereof.
AR115069A1 (en) SYNTHETIC CHEMERIC VACCINE VIRUS
CO2021010786A2 (en) Inactivated apxia, apxiia, and apxiiia toxins
BR112023005043A2 (en) VACCINE AGAINST COVID-19 BASED ON PIV5
BR112015032556A2 (en) MODIFIED MATRIX PROTEIN (M) FROM A VESICULAR STOMATITIS VIRUS (VSV); NUCLEOTIDE SEQUENCE ENCODING A MODIFIED MATRIX PROTEIN OF A VESICULAR STOMATITIS VIRUS; RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV); VACCINE; PREPARATION AND BOOST COMBINATION VACCINE; KIT; ISOLATED PEPTIDE; ISOLATED NUCLEOTIDE SEQUENCES; USE OF THE VACCINE; USE OF THE PREPARATION AND BOOST COMBINATION VACCINE; METHOD FOR INDUCING AN IMMUNE RESPONSE IN AN INDIVIDUAL
CL2021002307A1 (en) Use of oncolytic viruses for cancer treatment
AR108014A1 (en) UNIVERSAL VACCINE FOR VIRAL DISEASES AND VACCINATION METHOD
BR112022017032A2 (en) COMPOSITIONS INCLUDING LTB AND PATHOGENIC ANTIGENS, AND USE THEREOF.
UY36616A (en) VARIOUS FUSIONS III OF THE EPIDERMAL-MESOTHELINE GROWTH FACTOR RECEPTOR AND METHODS TO USE THE SAME
CO2022003004A2 (en) Genetically engineered oncolytic vaccinia viruses and methods of using the same
AR117808A1 (en) RECOMBINANT VACCINE VIRUS AND METHODS OF USE OF THE SAME
AR117877A1 (en) RECOMBINANT RHABDOVIRUS CODING CCL21
DOP2020000104A (en) METHODS OF USE AND COMPOSITIONS CONTAINING DULAGLUTIDA
BR112018072592A2 (en) yeast vaccine vector that includes immunostimulating and antigenic polypeptides, and methods of using them
AR115070A1 (en) STEM CELLS CONTAINING A SYNTHETIC CHIMERICAL VACCINE VIRUS AND METHODS FOR ITS USE